The annotation of Dyadic's re-sequenced C1 genome will be conducted at Scripps Florida under the direction of Bruce Pascal, Principal Investigator on Collaborative Proposal and Senior Scientific Engineer. Researchers from Dyadic Nederland B.V., Dyadic's research and development arm in the Netherlands ("Dyadic Netherlands"), will continue to work closely with researchers from Scripps Florida during this project. Financial details of the agreement were not disclosed.
Mark Emalfarb, Dyadic's CEO, stated, "The re-annotated C1 genome developed with Scripps Florida will provide Dyadic and its commercial partners with a more accurate blueprint of the C1 fungal strain which serves as the primary engine for Dyadic's growth. This research will help Dyadic make greater quantities of more efficient enzymes and proteins at lower costs to help provide solutions to problems facing the world such as using cellulosic ethanol to help reduce our dependence on foreign oil. In the biopharmaceutical industry, we intend to further utilize our technologies to help develop antibodies and other therapeutic proteins in a shorter time, at larger volumes and at lower costs. This collaboration also further underscores the strong relationship between Dyadic and Scripps as well as Dyadic's continued commitment to the development of a successful biotechnology cluster in South Florida."
Bruce Pascal of Scripps Florida added, "We are delighted to continue our collaboration with Dyadic. In the past few years, much new fungal genome data has become available, as well as new approaches for data analysis and interpretation. Our expertise in informatics, data analysis and software engineering, when combined with the C1 fungal genome should yield a powerful resource for understanding gene function, and development of important enzymes. Our goal is to facilitate the analysis and interpretation of complex data to ultimately create value from the C1 fungal genome. We also
|SOURCE Dyadic International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved